Screening for Alzheimer’s disease in primary care using an AI driven screening platform: design of the PREDICTOM study

Recent developments in physiological and digital biomarkers provide an opportunity to shift the first diagnostic steps to the homesetting, thus allowing earlier detection and treatment of Alzheimer’s disease (AD). Bloodbased, magnetic resonance imaging, electrophysiological, digital and microbiome biomarkers have shown great promise and call for an evaluation of their accuracy, feasibility and safety in primary care and the community. The aim of PREDICTOM is to develop and test the accuracy of an artificial intelligence (AI) driven screening platform for the prediction and early detection of AD and to extend the clinical pathway to homebased screening using established and novel biomarkers.